Dr. Reddy's Laboratories Limited (RDY)

NYSE: RDY · Real-Time Price · USD

Compare

14.14

-0.17 (-1.19%)

At close: Feb 13, 2026, 4:00 PM EST

14.09

-0.05 (-0.35%)

After-hours: Feb 13, 2026, 7:00 PM EST

Dr. Reddy's Laboratories Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	345,831	325,535	279,164	245,879	214,391	189,722
Revenue Growth (YoY)	11.09%	16.61%	13.54%	14.69%	13.00%	8.66%
Cost of Revenue	154,995	135,107	115,557	106,536	100,551	86,645
Gross Profit	190,836	190,428	163,607	139,343	113,840	103,077
Selling, General & Admin	102,039	92,853	76,921	68,026	62,081	54,650
Research & Development	25,853	27,380	22,873	19,381	17,482	16,541
Other Operating Expenses	-3,508	-2,836	-1,775	-1,480	-1,642	-1,024
Operating Expenses	124,384	117,397	98,019	85,927	77,921	70,167
Operating Income	66,452	73,031	65,588	53,416	35,919	32,910
Interest Expense	-3,337	-2,829	-1,711	-1,428	-958	-970
Interest & Investment Income	3,400	2,677	2,278	1,180	965	826
Earnings From Equity Investments	143	217	147	370	703	480
Currency Exchange Gain (Loss)	3,235	1,322	278	2,225	1,835	1,240
Other Non Operating Income (Expenses)	2,566	3,554	3,149	876	277	557
EBT Excluding Unusual Items	72,459	77,972	69,729	56,639	38,741	35,043
Merger & Restructuring Charges	-1,017	-1,017	-280	-	-	-
Gain (Loss) on Sale of Assets	1,514	1,522	900	-1,211	1,119	-42
Asset Writedown	-1,701	-1,693	-3	-699	-7,562	-8,588
Legal Settlements	748	-	1,524	5,638	-	-
Other Unusual Items	877	-	-	-	-	-
Pretax Income	72,880	76,784	71,870	60,367	32,298	26,413
Income Tax Expense	16,747	19,539	16,186	15,300	8,730	9,175
Earnings From Continuing Operations	56,133	57,245	55,684	45,067	23,568	17,238
Minority Interest in Earnings	454	-701	-	-	-	-
Net Income	56,587	56,544	55,684	45,067	23,568	17,238
Net Income to Common	56,587	56,544	55,684	45,067	23,568	17,238
Net Income Growth	5.42%	1.54%	23.56%	91.22%	36.72%	-11.59%
Shares Outstanding (Basic)	833	833	832	830	829	829
Shares Outstanding (Diluted)	833	834	834	832	832	832
Shares Change (YoY)	-0.15%	0.08%	0.19%	0.03%	0.01%	0.14%
EPS (Basic)	67.97	67.88	66.93	54.29	28.42	20.79
EPS (Diluted)	67.93	67.78	66.80	54.17	28.34	20.73
EPS Growth	5.58%	1.47%	23.32%	91.16%	36.70%	-11.71%
Free Cash Flow	36,656	18,924	29,030	47,552	13,448	25,962
Free Cash Flow Per Share	44.01	22.69	34.83	57.16	16.17	31.22
Dividend Per Share	8.000	8.000	8.000	8.000	6.000	5.000
Dividend Growth	-	-	-	33.33%	20.00%	-
Gross Margin	55.18%	58.50%	58.61%	56.67%	53.10%	54.33%
Operating Margin	19.21%	22.43%	23.49%	21.73%	16.75%	17.35%
Profit Margin	16.36%	17.37%	19.95%	18.33%	10.99%	9.09%
Free Cash Flow Margin	10.60%	5.81%	10.40%	19.34%	6.27%	13.68%
EBITDA	84,786	88,840	79,286	66,052	47,743	45,706
EBITDA Margin	24.52%	27.29%	28.40%	26.86%	22.27%	24.09%
D&A For EBITDA	18,334	15,809	13,698	12,636	11,824	12,796
EBIT	66,452	73,031	65,588	53,416	35,919	32,910
EBIT Margin	19.21%	22.43%	23.49%	21.73%	16.75%	17.35%
Effective Tax Rate	22.98%	25.45%	22.52%	25.35%	27.03%	34.74%

Updated Jan 21, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q